Carcinogenesis, Vol. 20, No. 10, 2003-2009,
October 1999
© 1999 Oxford University Press
Carcinogenesis |
N-Demethylation accompanies 
-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
Institute of Cancer Research, Haddow Laboratories, Cotswold Road, Sutton SM2 5NG, UK
Previous work has shown that a major route of activation of tamoxifen to DNA-binding products in rat liver cells is via 
-hydroxylation leading to modification of the N2-position of guanine in DNA and to a lesser extent the N6-position of adenine. Improved resolution by HPLC has now identified two major adducts in rat liver DNA, one of them the aforementioned tamoxifen–N2-guanine adduct and the other the equivalent adduct in which the tamoxifen moiety has lost a methyl group. Treatment of rats or rat hepatocytes with N-desmethyltamoxifen gave rise to the second adduct, whereas treatment with tamoxifen or -hydroxytamoxifen gave rise to both. Furthermore, N,N-didesmethyltamoxifen was found to be responsible for an additional minor DNA adduct formed by tamoxifen, -hydroxytamoxifen and N-desmethyltamoxifen. The involvement of metabolism at the position was confirmed in experiments in which [-D2-ethyl]tamoxifen, but not [ß-D3-ethyl]tamoxifen, produced reduced levels of DNA adducts. Tamoxifen N-oxide and -hydroxytamoxifen N-oxide also gave rise to DNA adducts in rat liver cells, but the adduct patterns were very similar to those formed by tamoxifen and -hydroxytamoxifen, indicating that the N-oxygen is lost prior to DNA binding. These and earlier results demonstrate that in rat liver cells in vivo and in vitro, Phase I metabolic activation of tamoxifen involves both -hydroxylation and N-demethylation, which is followed by Phase II activation at the -position to form a highly reactive sulphate. Detection of tamoxifen-related DNA adducts by 32P-postlabelling is achieved with >90% labelling efficiency.
Abbreviations: [-D2-ethyl]tamoxifen, [3,3-2H2]-(Z)-1-[4-[2-(dimethylamino)-ethoxy]phenyl]-1,2-diphenyl-1-butene; [ß-D3-ethyl]tamoxifen, [4,4,4-2H3]-(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenyl-1-butene; [D5-ethyl]tamoxifen, [3,3,4,4,4-2H5]-(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenyl-1-butene; PEI, polyethyleneimine; tamoxifen, (Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenyl-1-butene.
1 Present address: Imperial College School of Medicine, Division of Biomedical Sciences, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, UK
2 To whom correspondence should be addressed Email: davidp{at}icr.ac.uk
Deceased. Formerly of CRC Centre for Cancer Therapeutics, Institute of Cancer Research,Cotswold Road, Sutton SM2 5NG, UK
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods Mutagenesis, March 1, 2005; 20(2): 115 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Beland, M. I. Churchwell, D. R. Doerge, D. R. Parkin, D. Malejka-Giganti, A. Hewer, D. H. Phillips, P. L. Carmichael, G. Gamboa da Costa, and M. M. Marques Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in Humans J Natl Cancer Inst, July 21, 2004; 96(14): 1099 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kasahara, M. Hashiba, T. Harada, and M. Degawa Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats Carcinogenesis, March 1, 2002; 23(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al. Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction Cancer Res., June 1, 2000; 60(11): 2887 - 2891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients Carcinogenesis, April 1, 2000; 21(4): 845 - 847. [Abstract] [Full Text] [PDF]
|
|